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Metastasis to the brain is a late step 
in the progression of many solid tumors 
including breast cancer, lung cancer and 
melanoma.1,2 In the clinic brain metas-
tases are more frequently seen in recent 
years,3 a fact that is thought to be due to 
advances in the systemic treatment of the 
underlying malignancy (for example in 
breast cancer) and also to increasing rates 
of some tumors such as malignant mela-
noma. Brain metastases diminish qual-
ity of life and shorten survival of patients 
with advanced cancer.1–4 The biology of 
brain metastases, which includes the fact 
that they often present as multiple foci in 
intracerebral sites, and their relative pro-
tection from systemic therapies by the 
blood-brain barrier, present serious chal-
lenges to therapy. Currently, the treatment 
of brain metastases is similar to that for 
primary brain tumors, mainly radiother-
apy and neurosurgical resection.3,4 These 
treatments are more palliative than cura-
tive. New, effective therapies are sorely 
needed to improve patient outcomes.
We are exploring targeted therapies for 
the treatment of brain metastases in pre-
clinical models. One treatment modality 
that we view as very promising is cellular 
immunotherapy using alloreactive cyto-
toxic T lymphocytes (alloCTL). AlloCTL, 
lymphocytes from unrelated blood donors 
that are sensitized to the human leuko-
cyte antigens (HLA) of the tumor-bearing 
host, target brain cancer cells because they 
display HLA whereas normal neuroglia 
do not. AlloCTL have demonstrated in 
vitro and in vivo promise in preclinical 
glioma model studies5 and are currently 
being tested in a Phase I dose escalation 
trial in recurrent glioma (NCT01144247; 
www.clinicaltrials.gov). A different treat-
ment modality for glioma uses replicat-
ing retroviral vectors (RRV) to deliver 
a prodrug activating enzyme that when 
followed with prodrug has shown benefi-
cial preclinical results.6,7 The therapeutic 
RRV encode yeast cytosine deaminase 
(RRV-CD) that activates the prodrug 
5-fluorocytosine (5FC) into toxic 5-fluo-
rouracil (5FU). In quiescent brain, RRV 
preferentially infects dividing brain cancer 
cells. RRV with prodrug is currently being 
explored in the clinic as an experimental 
treatment for glioma (NCT01156584 and 
NCT01470794; www.clinicaltrials.gov). 
Recently, we assessed the therapeutic effi-
cacy of alloCTL and RRV used individu-
ally or in combination in xenograft models 
of human breast cancer.8
To generate alloCTL that recognize 
and attack the MDA-MB-231 (231) 
human breast tumor cell line, peripheral 
blood mononuclear cells were isolated 
from healthy, HLA-mismatched donors 
and combined with gamma-irradiated 
231 cells in a one-way mixed lymphocyte 
tumor reaction. The resulting alloCTL 
were mainly CD3+/CD8+ T cells that pro-
liferated and produced proinflammatory 
IFNγ when coincubated with breast can-
cer targets and displayed potent cytotoxic-
ity against 231 cells and the brain seeking 
subline 231BR in vitro. In immune defi-
cient mice, alloCTL were placed into a 
231BR tumor focus, induced tumor cell 
apoptosis and trafficked toward another 
established tumor focus in contralateral 
brain, where they also caused tumor cell 
injury.8
The efficacies of individual and com-
bined alloCTL and RRV therapies were 
tested in subcutaneous and intracranial 
established 231 tumor xenograft models 
in immune deficient mice. Subcutaneous 
tumor growth was significantly reduced in 
alloCTL and gene therapy treated groups 
compared with controls, with the larg-
est reduction in tumor volume observed 
in mice treated with both alloCTL and 
RRV-CD + 5FC. In an intracranial model, 
we show that RRV efficiently transduce 
231BR intracranial tumors without detect-
able spread to normal brain. Further, 
mice with established intracranial 231BR 
tumors treated with combined alloCTL 
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and RRV-CD showed a significant survival 
advantage over single therapeutic modali-
ties (median survival time 97.5 d com-
pared with 50–83 d) and all experimental 
treatment groups survived significantly 
longer than sham-treated groups (median 
survivals 31.5 or 40 d). Vector biodistribu-
tion studies within the brain and in extra-
tumoral tissues showed the safety of the 
approaches, and long-term survivors in 
gene therapy treatment groups had low or 
no detectable levels of RRV signals corre-
lating with the apparent absence of tumor 
by histopathology. Overall, combining 
the novel alloCTL and RRV approaches 
provided multiple mechanisms of tumor 
cell targeted cytotoxicity, including cyto-
toxic T lymphocyte effector-mediated and 
chemotherapeutic-mediated cytolysis with 
suicide vector/prodrug that may be fur-
ther promoted with bystander effects. The 
combined therapies are also well tolerated 
and brain sparing.
Our results demonstrate proof-of-con-
cept that a unique combination regimen 
consisting of cellular immune and gene 
therapy approaches is a viable strategy for 
treatment of established brain metastases. 
As alloCTL and RRV therapies have now 
individually reached the clinical testing 
stage, we can envision the clinical design 
for combination immunogene therapy of 
intracranial tumors to be feasible (Fig. 1). 
It is further conceivable that other 
approaches such as active immunotherapy 
with dendritic cell vaccination could be 
added to further augment the immune 
response to the tumor.9,10 FDA approval 
for dendritic cell vaccine therapy for pros-
tate cancer represents an encouraging 
forward step toward the use of immune 
therapy as part of a first line regimen. The 
use of a multi-modal approach will advan-
tageously lead to additive or even synergis-
tic effects elicited by multiple mechanisms 
of action, i.e., local cytotoxic apoptosis, 
chemotherapeutic lysis, the generation of 
an endogenous memory T cell response 
with proinflammatory cytokine produc-
tion, and tumor microenvironmental shift 
from an immunosuppressive to an effec-
tor-friendly state. Continued preclinical 
and clinical investigation of combined, 
local cellular, gene and vaccine therapy 
regimens are warranted for primary brain 
tumors and brain metastases.
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Figure 1. a clinical study design formulated for immuno-gene therapy of brain metastases. The steps show: (A) PBMC isolated from patient blood are 
expanded with high dose Interleukin-2 and OKT3 to serve as stimulators. (B) expanded stimulators are inactivated by irradiation. (C) Precursor alloreac-
tive CTL (alloCTL) are derived from healthy allodonor PBMC, are partially hLa-disparate to the patient, and serve as responders. (D) effector alloCTL are 
generated by one-way mixed lymphocyte reaction (MLr); inactivated stimulators are mixed with responders and cultured with low-dose Interleukin-2. 
(E) Patient undergoes a craniectomy for installation of a reservoir/catheter and to receive an intracranial implant of alloCTL and rrV coding for cytosine 
deaminase (rrV-CD); one week later more alloCTL + rrV-CD are infused through the catheter. (F) Three weeks following the last intracranial infusate 
the prodrug, 5-flurocytosine (5FC), is administered daily for 5 d to complete a treatment cycle. Multiple treatment cycles are possible. Different hLa-
mismatched allodonors are used at each cycle.
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